Hong Kong Exchanges and Clearing will implement listing rule changes that will become effective as early as June. The proposed regulatory reform will greatly facilitate the listing of “new-economy” companies in Hong Kong, including those in the life sciences and biotechnology industries, and also create greater diversity and investment opportunities to investors in Hong Kong and China.
In view of this development, Sidley hosted a breakfast roundtable on the topic of “How Companies in the Life Sciences and Biotechnology Sectors Capture Opportunities under the New Hong Kong Listing Regime” at the JW Marriott Hotel Hong Kong on January 29. Partners Constance Choy, Wenseng Wendy Pan and Mengyu Lu from Sidley shared their insights on the proposed listing rule changes and discussed how the listing reform would expand the existing listing system to attract “new-economy” companies and its implication to the life sciences and biotechnology companies in particular. The event also provided a valuable networking opportunity for companies who are contemplating raising capital in Hong Kong or interested in investing particularly in the life sciences and biotechnology industries.
This interactive networking event was attended by a number of c-suites and founders from around 15 Chinese life sciences companies, representing innovative biotechnology companies that develop small molecule and biologicals, medical devices companies and companies specializing in personalized diagnostic products, as well as potential investors from major investment banks and private equity companies.